Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody

Wang,Dongyang; Guo,Yuanxu; Li,Yanqing; Li,Weiling; Zheng,Xiaojing; Xia,Haibin; Mao,Qinwen

doi:10.3892/ol.2015.3079

Detection of CD133 expression in U87 glioblastoma cells using a novel anti-CD133 monoclonal antibody

Authors:
- Dongyang Wang
- Yuanxu Guo
- Yanqing Li
- Weiling Li
- Xiaojing Zheng
- Haibin Xia
- Qinwen Mao
View Affiliations

Affiliations: Co‑Innovation Center for Qinba Regions' Sustainable Development, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi 710062, P.R. China, Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Published online on: March 27, 2015 https://doi.org/10.3892/ol.2015.3079
Pages: 2603-2608

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In glioblastomas, the surface glycoprotein CD133 (prominin-1) indicates the presence of cancer stem cells (CSCs), which are able to initiate tumor growth and are highly resistant to conventional chemo/radiotherapy. However, a number of studies have reported that certain CD133‑ glioma cells are able to self‑renew and retain tumorigenic potential. In addition, the reliability of CD133 as a CSC marker is controversial due to inconsistent findings with regard to the prognostic values and distribution of CD133. Such controversies may be due to the detection limits using currently available anti‑CD133 antibodies. In the present study, novel anti‑human CD133 monoclonal antibodies (mAbs) were generated using two recombinant extracellular domains of human CD133: CD133 ectodomain 1 (amino acids 171‑420) and CD133 ectodomain 2 (amino acids 507‑716). One of the antibodies produced against CD133 ectodomain 2, C2E1, detected high expression levels of CD133 protein in glioblastoma U87 cells, in contrast to previous studies which did not detect CD133 expression in these cells. The cells exhibited a cytoplasmic distribution pattern of CD133 and produced a 95 kDa band following western blot analysis. In addition, C2E1 was able to bind the full‑length glycosylated CD133 on the cell surface and inhibit the proliferation of tumor cells. Therefore, this antibody may be a valuable tool to study CD133 as a CSC marker and may be significant in future cancer treatments.

View Figures

View References

1	Ostrom QT, Gittleman H, Liao P, et al: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 16:(Suppl 4). iv1–iv63. 2014. View Article : Google Scholar : PubMed/NCBI
2	Verdecchia A, De Angelis G and Capocaccia R: Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 21:3511–3526. 2002. View Article : Google Scholar : PubMed/NCBI
3	Weller M: Novel diagnostic and therapeutic approaches to malignant glioma. Swiss Med Wkly. 141:w132102011.PubMed/NCBI
4	McNamara MG, Sahebjam S and Mason WP: Emerging biomarkers in glioblastoma. Cancers (Basel). 5:1103–1119. 2013. View Article : Google Scholar : PubMed/NCBI
5	Stupp R, Hegi ME, Mason WP, et al: European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
6	Stupp R, Mason WP, van den Bent MJ, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
7	Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
8	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
9	Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
10	Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
11	Lim SH, Jang J, Park JO, et al: CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. J Gastrointest Oncol. 5:447–456. 2014.PubMed/NCBI
12	Mizugaki H, Sakakibara-Konishi J, Kikuchi J, et al: CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol. 19:254–259. 2014. View Article : Google Scholar : PubMed/NCBI
13	Hashimoto K, Aoyagi K, Isobe T, et al: Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer. 17:97–106. 2014. View Article : Google Scholar : PubMed/NCBI
14	Rappa G, Fodstad O and Lorico A: The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells. 26:3008–3017. 2008. View Article : Google Scholar : PubMed/NCBI
15	Wang CH, Chiou SH, Chou CP, et al: Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine. 7:69–79. 2011. View Article : Google Scholar : PubMed/NCBI
16	Clément V, Marino D, Cudalbu C, et al: Marker-independent identification of glioma-initiating cells. Nat Methods. 7:224–228. 2010. View Article : Google Scholar : PubMed/NCBI
17	Clément V, Dutoit V, Marino D, Dietrich PY and Radovanovic I: Limits of CD133 as a marker of glioma self-renewing cells. Int J Cancer. 125:244–248. 2009. View Article : Google Scholar : PubMed/NCBI
18	Wang J, Sakariassen PØ, Tsinkalovsky O, et al: CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 122:761–768. 2008. View Article : Google Scholar : PubMed/NCBI
19	Beier D, Hau P, Proescholdt M, et al: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:4010–4015. 2007. View Article : Google Scholar : PubMed/NCBI
20	Hermansen SK, Christensen KG, Jensen SS and Kristensen BW: Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem. 59:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zeppernick F, Ahmadi R, Campos B, et al: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
22	Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ and Molven A: Expression of the ‘stem cell marker’ CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 8:482008. View Article : Google Scholar : PubMed/NCBI
23	Thon N, Damianoff K, Hegermann J, et al: Presence of pluripotent CD133⁺ cells correlates with malignancy of gliomas. Mol Cell Neurosci. 43:51–59. 2010. View Article : Google Scholar : PubMed/NCBI
24	Beier D, Wischhusen J, Dietmaier W, et al: CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol. 18:370–377. 2008. View Article : Google Scholar : PubMed/NCBI
25	Pallini R, Ricci-Vitiani L, Banna GL, et al: Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 14:8205–8212. 2008. View Article : Google Scholar : PubMed/NCBI
26	Christensen K, Schrøder HD and Kristensen BW: CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol. 90:157–170. 2008. View Article : Google Scholar : PubMed/NCBI
27	Bidlingmaier S, Zhu X and Liu B: The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl). 86:1025–1032. 2008. View Article : Google Scholar : PubMed/NCBI
28	Florek M, Haase M, Marzesco AM, et al: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 319:15–26. 2005. View Article : Google Scholar : PubMed/NCBI
29	Jordan M, Schallhorn A and Wurm FM: Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 24:596–601. 1996. View Article : Google Scholar : PubMed/NCBI
30	Shmelkov SV, St Clair R, Lyden D and Rafii S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol. 37:715–719. 2005. View Article : Google Scholar : PubMed/NCBI
31	Plumb JA, Milroy R and Kaye SB: Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 49:4435–4440. 1989.PubMed/NCBI
32	Campos B and Herold-Mende CC: Insight into the complex regulation of CD133 in glioma. Int J Cancer. 128:501–510. 2011. View Article : Google Scholar : PubMed/NCBI
33	Wu A, Oh S, Wiesner SM, et al: Persistence of CD133⁺ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev. 17:173–184. 2008. View Article : Google Scholar : PubMed/NCBI
34	Platet N, Liu SY, Atifi ME, et al: Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 258:286–290. 2007. View Article : Google Scholar : PubMed/NCBI
35	Christensen K, Aaberg-Jessen C, Andersen C, Goplen D, Bjerkvig R and Kristensen BW: Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. Neurosurgery. 66:933–947. 2010. View Article : Google Scholar : PubMed/NCBI
36	Corbeil D, Röper K, Hellwig A, et al: The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 275:5512–5520. 2000. View Article : Google Scholar : PubMed/NCBI
37	Miraglia S, Godfrey W, Yin AH, et al: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 90:5013–5021. 1997.PubMed/NCBI
38	Mizrak D, Brittan M and Alison M: CD133: molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
39	Fargeas CA, Huttner WB and Corbeil D: Nomenclature of prominin-1 (CD133) splice variants - an update. Tissue Antigens. 69:602–606. 2007. View Article : Google Scholar : PubMed/NCBI
40	Jaszai J, Fargeas CA, Florek M, Huttner WB and Corbeil D: Focus on molecules: prominin-1 (CD133). Exp Eye Res. 85:585–586. 2007. View Article : Google Scholar : PubMed/NCBI
41	Fargeas CA, Joester A, Missol-Kolka E, Hellwig A, Huttner WB and Corbeil D: Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci. 117:4301–4311. 2004. View Article : Google Scholar : PubMed/NCBI